{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:08:46Z","timestamp":1791576526893,"version":"4.3.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T00:00:00Z","timestamp":1547164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1038\/s41375-018-0346-z","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T13:47:05Z","timestamp":1547214425000},"page":"1124-1134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["KIT D816 mutated\/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis"],"prefix":"10.1038","volume":"33","author":[{"given":"Mohamad","family":"Jawhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstanze","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kreil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Schwaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Shoumariyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manja","family":"Meggendorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert L. F.","family":"Span","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Fuhrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Naumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Horny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Sotlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Kubuschok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"von Bubnoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Spiekermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Metzgeroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Fabarius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Karsten","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke C.","family":"Kluin-Nelemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5481-2555","authenticated-orcid":false,"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,11]]},"reference":[{"key":"346_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","volume":"37","author":"P Valent","year":"2007","unstructured":"Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435\u201353.","journal-title":"Eur J Clin Invest"},{"key":"346_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","volume":"25","author":"P Valent","year":"2001","unstructured":"Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25:603\u201325.","journal-title":"Leuk Res"},{"key":"346_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1056\/NEJMra1409760","volume":"373","author":"TC Theoharides","year":"2015","unstructured":"Theoharides TC, Valent P, Akin C. mast Cells, mastocytosis, and related disorders. N Engl J Med. 2015;373:163\u201372.","journal-title":"N Engl J Med"},{"key":"346_CR4","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/ajh.23459","volume":"88","author":"A Pardanani","year":"2013","unstructured":"Pardanani A. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Am J Hematol. 2013;88:612\u201324.","journal-title":"Am J Hematol"},{"key":"346_CR5","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1182\/blood-2010-06-289959","volume":"118","author":"KV Gleixner","year":"2011","unstructured":"Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hormann G, Rix U, Bennett KL, et al. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood. 2011;118:1885\u201398.","journal-title":"Blood"},{"key":"346_CR6","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","volume":"108","author":"AC Garcia-Montero","year":"2006","unstructured":"Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108:2366\u201372.","journal-title":"Blood"},{"key":"346_CR7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/mp.53.4.188","volume":"53","author":"K Sotlar","year":"2000","unstructured":"Sotlar K, Marafioti T, Griesser H, Theil J, Aepinus C, Jaussi R, et al. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. J Clin Pathol Mol Pathol. 2000;53:188\u201393.","journal-title":"J Clin Pathol Mol Pathol"},{"key":"346_CR8","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/path.2677","volume":"220","author":"K Sotlar","year":"2010","unstructured":"Sotlar K, Colak S, Bache A, Berezowska S, Krokowski M, Bultmann B, et al. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol. 2010;220:586\u201395.","journal-title":"J Pathol"},{"key":"346_CR9","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","volume":"122","author":"J Schwaab","year":"2013","unstructured":"Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122:2460\u20136.","journal-title":"Blood"},{"key":"346_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/leu.2015.284","volume":"30","author":"M Jawhar","year":"2016","unstructured":"Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, et al. Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia. 2016;30:136\u201343.","journal-title":"Leukemia"},{"key":"346_CR11","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/ajh.24426","volume":"91","author":"A Pardanani","year":"2016","unstructured":"Pardanani A, Lasho T, Elala Y, Wassie E, Finke C, Reichard KK, et al. Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival. Am J Hematol. 2016;91:888\u201393.","journal-title":"Am J Hematol"},{"key":"346_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/leu.2015.4","volume":"29","author":"M Jawhar","year":"2015","unstructured":"Jawhar M, Schwaab J, Schnittger S, Sotlar K, Horny HP, Metzgeroth G, et al. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. Leukemia. 2015;29:1115\u201322.","journal-title":"Leukemia"},{"key":"346_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00277-012-1580-5","volume":"92","author":"HJ Kim","year":"2013","unstructured":"Kim HJ, Ahn HK, Jung CW, Moon JH, Park CH, Lee KO, et al. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1\/RUNX1T1 rearrangement. Ann Hematol. 2013;92:163\u201371.","journal-title":"Ann Hematol"},{"key":"346_CR14","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00277-017-3074-y","volume":"96","author":"S Yui","year":"2017","unstructured":"Yui S, Kurosawa S, Yamaguchi H, Kanamori H, Ueki T, Uoshima N, et al. D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations. Ann Hematol. 2017;96:1641\u201352.","journal-title":"Ann Hematol"},{"key":"346_CR15","doi-asserted-by":"publisher","unstructured":"Hilmi FAI, Al-Sabbagh A, Soliman DS, Sabah HA, Ismail OM, Yassin M, et al. Acute myeloid leukemia with Inv(16)(p13q22) associated with hidden systemic mastocytosis: case report and review of literature. Clin Med Insights Blood Disord. 2017;10. \n                    https:\/\/doi.org\/10.1117\/1179545X17700858\n                    \n                  .","DOI":"10.1117\/1179545X17700858"},{"key":"346_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jaci.2004.02.042","volume":"114","author":"L Escribano","year":"2004","unstructured":"Escribano L, Garca-Montero A, Nunez-Lopez R, Lopez-Jimenez J, Almeida J, Prados A, et al. Systemic mastocytosis associated with acute myeloid leukemia: case report and implications for disease pathogenesis. J Allergy Clin Immunol. 2004;114:28\u201333.","journal-title":"J Allergy Clin Immunol"},{"key":"346_CR17","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.leukres.2012.07.001","volume":"36","author":"E Cornet","year":"2012","unstructured":"Cornet E, Dumezy F, Roumier C, Lepelley P, Jouy N, Philippe N, et al. Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis. Leuk Res. 2012;36:1330\u20133.","journal-title":"Leuk Res"},{"key":"346_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.leukres.2006.03.006","volume":"31","author":"V Pullarkat","year":"2007","unstructured":"Pullarkat V, Bedell V, Kim Y, Bhatia R, Nakamura R, Forman S, et al. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res. 2007;31:261\u20135.","journal-title":"Leuk Res"},{"key":"346_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12308-009-0023-2","volume":"2","author":"ST Pullarkat","year":"2009","unstructured":"Pullarkat ST, Pullarkat V, Kroft SH, Wilson CS, Ahsanuddin AN, Mann KP, et al. Systemic mastocytosis associated with t(8;21)(q22; q22) acute myeloid leukemia. J Hematop. 2009;2:27\u201333.","journal-title":"J Hematop"},{"key":"346_CR20","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/eci.12607","volume":"46","author":"M Jawhar","year":"2016","unstructured":"Jawhar M, Schwaab J, Horny HP, Sotlar K, Naumann N, Fabarius A, et al. Imact of centralized evaluation of bone marrow histology in systemic mastocytosis. Eur J Clin Invest. 2016;46:392\u20137.","journal-title":"Eur J Clin Invest"},{"key":"346_CR21","first-page":"54","volume-title":"Pathology & genetics. Tumours of haematopoietic and lymphoid tissues","author":"HPAC Horny","year":"2008","unstructured":"Horny HPAC, Metcalfe DD, Swerdlow SH, Campo E, Harris NL, et al. World Health Organization (WHO) classification of tumours. Mastocytosis (Mast cell disease). Pathology & genetics. Tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. p. 54\u201363. Vol. 2."},{"key":"346_CR22","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;2391\u2013405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"346_CR23","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1002\/ajh.24553","volume":"91","author":"A Pardanani","year":"2016","unstructured":"Pardanani A. Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management. Am J Hematol. 2016;91:1146\u201359.","journal-title":"Am J Hematol"},{"key":"346_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","volume":"93","author":"P Erben","year":"2014","unstructured":"Erben P, Schwaab J, Metzgeroth G, Horny HP, Jawhar M, Sotlar K, et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol. 2014;93:81\u20138.","journal-title":"Ann Hematol"},{"key":"346_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000353118","volume":"141","author":"A Simons","year":"2013","unstructured":"Simons A, Shaffer LG, Hastings RJ. Cytogenetic nomenclature: changes in the ISCN 2013 compared to the 2009 Edition. Cytogenet Genome Res. 2013;141:1\u20136.","journal-title":"Cytogenet Genome Res"},{"key":"346_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/sj.leu.2402329","volume":"16","author":"C Schoch","year":"2002","unstructured":"Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 2002;16:53\u20139.","journal-title":"Leukemia"},{"key":"346_CR27","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"346_CR28","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"346_CR29","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3324\/haematol.2017.163964","volume":"102","author":"M Jawhar","year":"2017","unstructured":"Jawhar M, Schwaab J, Meggendorfer M, Naumann N, Horny HP, Sotlar K, et al. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica. 2017;102:1035\u201343.","journal-title":"Haematologica"},{"key":"346_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","volume":"130","author":"M Jawhar","year":"2017","unstructured":"Jawhar M, Schwaab J, Naumann N, Horny HP, Sotlar K, Haferlach T, et al. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood. 2017;130:137\u201345.","journal-title":"Blood"},{"key":"346_CR31","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/gcc.22526","volume":"57","author":"N Naumann","year":"2018","unstructured":"Naumann N, Jawhar M, Schwaab J, Kluger S, Lubke J, Metzgeroth G, et al. Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis. Genes Chromosomes Cancer. 2018;57:252\u20139.","journal-title":"Genes Chromosomes Cancer"},{"key":"346_CR32","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1182\/blood-2015-11-679167","volume":"128","author":"M Mossner","year":"2016","unstructured":"Mossner M, Jann JC, Wittig J, Nolte F, Fey S, Nowak V, et al. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. Blood. 2016;128:1246\u201359.","journal-title":"Blood"},{"key":"346_CR33","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","volume":"366","author":"MJ Walter","year":"2012","unstructured":"Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366:1090\u20138.","journal-title":"N Engl J Med"},{"key":"346_CR34","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1200\/JCO.2013.48.9120","volume":"31","author":"E Padron","year":"2013","unstructured":"Padron E, Abdel-Wahab O. Importance of genetics in the clinical management of chronic myelomonocytic leukemia. J Clin Oncol. 2013;31:2374\u20136.","journal-title":"J Clin Oncol"},{"key":"346_CR35","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616\u201327.","journal-title":"Blood"},{"key":"346_CR36","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1136\/jcp.2003.012864","volume":"57","author":"HW Bernd","year":"2004","unstructured":"Bernd HW, Sotlar K, Lorenzen J, Osieka R, Fabry U, Valent P, et al. Acute myeloid leukaemia with t(8;21) associated with \"occult\" mastocytosis. Report of an unusual case and review of the literature. J Clin Pathol. 2004;57:324\u20138.","journal-title":"J Clin Pathol."},{"key":"346_CR37","doi-asserted-by":"publisher","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","volume":"114","author":"A Pardanani","year":"2009","unstructured":"Pardanani A, Lim KH, Lasho TL, Finke C, McClure RF, Li CY, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009;114:3769\u201372.","journal-title":"Blood"},{"key":"346_CR38","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/ajh.23380","volume":"88","author":"SA Wang","year":"2013","unstructured":"Wang SA, Hutchinson L, Tang G, Chen SS, Miron PM, Huh YO, et al. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol. 2013;88:219\u201324.","journal-title":"Am J Hematol"},{"key":"346_CR39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241\u20137.","journal-title":"Leukemia"},{"key":"346_CR40","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1056\/NEJMoa1611604","volume":"376","author":"RC Lindsley","year":"2017","unstructured":"Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376:536\u201347.","journal-title":"N Engl J Med"},{"key":"346_CR41","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","volume":"31","author":"R Itzykson","year":"2013","unstructured":"Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31:2428\u201336.","journal-title":"J Clin Oncol"},{"key":"346_CR42","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Finke CM, Elala Y, Hanson CA, Ketterling RP, et al. Targeted deep sequencing in primary myelofibrosis. Blood Adv. 2016;1:105\u201311.","journal-title":"Blood Adv"},{"key":"346_CR43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1:21\u201330.","journal-title":"Blood Adv"},{"key":"346_CR44","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1182\/bloodadvances.2018015875","volume":"2","author":"TL Lasho","year":"2018","unstructured":"Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Szuber N, et al. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. Blood Adv. 2018;2:370\u201380.","journal-title":"Blood Adv"},{"key":"346_CR45","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1200\/JCO.2012.42.2907","volume":"30","author":"T Buchner","year":"2012","unstructured":"Buchner T, Schlenk RF, Schaich M, Dohner K, Krahl R, Krauter J, et al. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm\u2013combined prospective analysis by the German AML Intergroup. J Clin Oncol. 2012;30:3604\u201310.","journal-title":"J Clin Oncol"},{"key":"346_CR46","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","volume":"374","author":"J Gotlib","year":"2016","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. N Engl J Med. 2016;374:2530\u201341.","journal-title":"N Engl J Med"},{"key":"346_CR47","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/leu.2017.234","volume":"32","author":"DJ DeAngelo","year":"2018","unstructured":"DeAngelo DJ, George TI, Linder A, Langford C, Perkins C, Ma J, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2018;32:470\u20138.","journal-title":"Leukemia"},{"key":"346_CR48","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","volume":"106","author":"J Gotlib","year":"2005","unstructured":"Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005;106:2865\u201370.","journal-title":"Blood"},{"key":"346_CR49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/blood-2013-12-544197","volume":"124","author":"J Gotlib","year":"2014","unstructured":"Gotlib J, George T, Akin C, Sotlar K, et al. Midostaurin (PKC412) Demonstrates a high rate of durable responses in patients with advanced systemic mastocytosis: results from the fully accrued global phase 2 CPKC412D2201 trial. Blood. 2014;124:21.","journal-title":"Blood"},{"key":"346_CR50","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.iac.2018.04.005","volume":"38","author":"L Falchi","year":"2018","unstructured":"Falchi L, Verstovsek S. Kit mutations: new insights and diagnostic value. Immunol Allergy Clin North Am. 2018;38:411\u201328.","journal-title":"Immunol Allergy Clin North Am"},{"key":"346_CR51","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1182\/blood-2017-05-781278","volume":"130","author":"DJ DeAngelo","year":"2017","unstructured":"DeAngelo DJ, Quiery AT, Radia D, Drummond MW, Gotlib J, Robinson WA, et al. Clinical activity in a phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis. Blood. 2017;130:2.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0346-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0346-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0346-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:36:32Z","timestamp":1684618592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-018-0346-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,11]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["346"],"URL":"https:\/\/doi.org\/10.1038\/s41375-018-0346-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,11]]},"assertion":[{"value":"11 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H-PH, K Sotlar, PV, and AR served as consultants in a global phase-II-study examining the effects of midostaurin in advanced systemic mastocytosis. H-PH, K Sotlar, K Shoumariyeh, PV, NCPC, and AR received honoraria and\/or travel support from Novartis Pharmaceuticals. MJ and JS received travel support from Novartis Pharmaceuticals. TH has equity ownership of the MLL Munich Leukemia Laboratory. MM is employed by the MLL Munich Leukemia Laboratory. The remaining authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}